BGC-20-1531 free base (C09-1113-764)

BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headacheIn VitroBGC-20-1531 free base competitively antagonized PGE 2 -induced vasodilatation of human middle cerebral (pK b =7.8) and meningeal (pK b =7.6) arteries, but had no effect on responses induced by PGE 2 on coronary, pulmonary or renal arteries. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoBGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE 2 -induced increase in canine carotid blood flow . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Beagle dogs Dosage: 1-10 mg/kg Administration: I.v. Result: Caused a dose-dependent antagonism of the PGE 2 -induced increase in canine carotid blood flow.Form:SolidIC50& Target:EP4 7.6 (pKd). Specification: 0.98 Molecular Formula: C26H24N2O6S Molecular Weight: 492.54 PubChem CID: 18444613 Isomeric SMILES: CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC